MOTS-c
MOTS-c (Mitochondrial-Derived Peptide)
A naturally produced mitochondrial peptide that acts as an exercise mimetic, improving insulin sensitivity, fat metabolism, and physical performance by optimizing cellular energy use.

MOTS-c is a 16 amino acid peptide that your mitochondria, the tiny power plants inside every cell in your body, actually produce naturally. Unlike most peptides in the research space that are synthetic versions of hormones, MOTS-c is encoded directly in your mitochondrial DNA. Your body makes it in response to stress and exercise, and it helps regulate how your cells use energy. It was discovered in 2015 by researchers studying the mitochondrial genome, and since then it has generated significant interest for its ability to improve how your body handles glucose, enhance insulin sensitivity, and potentially slow certain aspects of aging.
What makes MOTS-c particularly interesting is that your natural levels decline as you get older. This decline lines up with the metabolic problems that come with aging: worse insulin sensitivity, more difficulty burning fat, less energy, and reduced physical capacity. In animal studies, supplementing with MOTS-c prevented diet-induced obesity, reversed insulin resistance even in older subjects, and improved physical performance in mice of all ages, including elderly mice equivalent to roughly 70 human years. Researchers have described it as an exercise mimetic because it triggers some of the same metabolic pathways that physical activity does.
MOTS-c is available through research peptide suppliers but has not undergone large-scale human clinical trials. A related compound called CB4211 has shown safety in early human studies, which provides some reassurance about the general approach. While the preclinical data is compelling, it is important to understand that MOTS-c is not a replacement for exercise or a dramatic weight loss drug like the GLP-1 medications. It is better understood as a metabolic optimizer that helps your cells work more efficiently.
How It Works
Think of your cells as tiny factories that convert food into energy. The key worker in this process is a molecule called NAD+, which acts like a shuttle carrying energy from the food you eat into the machinery that produces usable fuel. MOTS-c works by activating a master energy sensor inside your cells called AMPK. AMPK is like a factory supervisor that monitors energy levels. When AMPK gets activated, it tells the factory to switch into high-efficiency mode: burn fat for fuel, take up glucose from the blood more effectively, and build new mitochondria to increase overall energy production capacity. This is exactly what happens when you exercise, which is why MOTS-c is called an exercise mimetic.
What makes MOTS-c unusual among peptides is that it can actually enter the nucleus of your cells and change which genes are turned on and off. Under stress conditions, MOTS-c moves from the cell's main workspace into the control room and directly influences gene expression, particularly genes involved in antioxidant defense. This means it is not just sending a temporary metabolic signal; it is actually reprogramming your cells to handle stress better. The primary target tissue appears to be skeletal muscle, where MOTS-c enhances glucose uptake, improves insulin sensitivity, and helps muscle cells adapt to metabolic demands.
Exercise naturally increases your MOTS-c levels by about 12-fold, and researchers have confirmed that exercise induces MOTS-c expression in both skeletal muscle and the bloodstream in humans. Supplementing with exogenous MOTS-c appears to produce some of the same metabolic benefits: improved glucose handling, enhanced fat oxidation, better physical performance, and reduced inflammation through the downregulation of inflammatory markers including IL-6, IL-1-beta, and TNF-alpha. Recent research has also shown potential benefits for bone health, with MOTS-c promoting bone-building cell activity while inhibiting bone-breakdown cells.
Potential Benefits
Improved Insulin Sensitivity
This is the most well-documented effect of MOTS-c. In animal studies, treatment reversed diet-induced insulin resistance and improved glucose tolerance, with significant effects observed even in older animals whose metabolic function had declined with age.
Prevention of Diet-Induced Obesity
Mice treated with MOTS-c while eating a high-fat diet gained significantly less weight than untreated controls. The compound enhances fat burning and prevents the metabolic dysfunction that normally develops with chronic overfeeding.
Enhanced Physical Performance
MOTS-c treatment improved physical performance in mice of all ages, including elderly mice. Even when started late in life, equivalent to roughly 70 human years, the compound improved running capacity and muscle function.
Potential Anti-Aging Effects
MOTS-c levels naturally decline with age, and this decline correlates with worsening metabolic function. Restoring levels in older animals improved markers associated with healthy aging, and the compound reduced signs of aging in pancreatic cells.
Reduced Inflammation
MOTS-c downregulates inflammatory markers including IL-6, IL-1-beta, and TNF-alpha. Since chronic inflammation drives metabolic disease and accelerates aging, this anti-inflammatory effect may contribute to broader health benefits beyond fat loss.
Cardiovascular and Bone Health
Animal studies show MOTS-c improves cardiac function and reduces damage from type 2 diabetes. Recent research also shows it promotes bone-building cell activity while inhibiting bone-breakdown cells, suggesting potential benefits for bone health.
What the Research Shows
The initial discovery study, published in Cell Metabolism in 2015, identified MOTS-c and demonstrated that it regulates insulin sensitivity and metabolic balance in mice. Treatment prevented both age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. Mice that received MOTS-c while eating a high-fat diet gained significantly less weight than untreated controls, and the compound appeared to enhance fat burning and prevent the metabolic dysfunction that normally comes with chronic overfeeding.
A 2021 study published in Nature Communications took the research further by showing that MOTS-c improves physical performance in mice of all ages. Even when treatment started late in life, at the mouse equivalent of roughly 70 human years, it improved running capacity and muscle function. The same study confirmed that exercise induces endogenous MOTS-c expression in human skeletal muscle and circulation, providing direct evidence that the peptide plays a natural role in exercise adaptation. Separately, a CB4211 trial, using a synthetic analog of MOTS-c, found the compound safe and well tolerated in a Phase 1 human study.
More recent research has expanded the known benefits of MOTS-c. A 2023 study in Frontiers in Physiology showed it promotes bone-building cell proliferation and inhibits bone-breakdown cell production, suggesting potential applications for bone health and osteoporosis. A 2025 study in Experimental and Molecular Medicine demonstrated that MOTS-c treatment reduced signs of aging in pancreatic cells and improved their function, which is relevant because MOTS-c levels are lower in people with type 2 diabetes compared to healthy controls. The compound also downregulates inflammatory markers including IL-6, IL-1-beta, and TNF-alpha, and improves cardiac function in animal models.
What to Know
Reported side effects are generally mild and include injection site reactions such as redness, swelling, or bruising, mild fatigue or lethargy when first starting as the body adjusts to AMPK activation, changes in appetite, and possible sleep disturbance if dosed late in the day. Occasional headache and mild GI discomfort have also been reported.
MOTS-c has not undergone large-scale human safety trials, so long-term effects are unknown. There are theoretical concerns about cancer risk because MOTS-c may affect cell proliferation pathways. Some research suggests it could be therapeutic for cancer, while other studies raise concerns about promoting certain cancer types. People with active cancer or a history of cancer should avoid this compound. MOTS-c is on the WADA prohibited list and should not be used by athletes in tested sports.
Those with type 1 diabetes or any serious chronic illness should use caution. MOTS-c affects glucose metabolism, so people taking diabetes medications should monitor blood sugar closely. Not studied in pregnant or breastfeeding women and should be avoided during pregnancy.
Research References
The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
Lee C, Zeng J, Drew BG, et al. · Cell Metabolism · 2015
Landmark discovery paper identifying MOTS-c as a mitochondrial-encoded peptide that regulates insulin sensitivity, prevents diet-induced obesity, and reverses age-dependent insulin resistance in mice.
View StudyMOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Reynolds JC, Lai RW, Woodhead JST, et al. · Nature Communications · 2021
Demonstrated that MOTS-c improves physical performance in mice of all ages including elderly mice, confirmed that exercise induces MOTS-c expression in human skeletal muscle, and established it as an exercise-induced mitochondrial regulator.
View StudyMitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging
Wan W, Zhang L, Lin Y, et al. · Journal of Translational Medicine · 2023
Comprehensive review of MOTS-c's effects on stress response, metabolism, and aging, covering its AMPK activation mechanism, nuclear translocation capabilities, and anti-inflammatory properties.
View StudyMitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes
Kong BS, Lee C, Cho YM, et al. · Experimental & Molecular Medicine · 2025
Showed that MOTS-c treatment reduced signs of aging in pancreatic cells and improved their function, with clinical relevance supported by finding that MOTS-c levels are lower in type 2 diabetes patients compared to healthy controls.
View Study